A Replication-deficient H9N2 Influenza Virus Carrying H5 Hemagglutinin Conferred Protection Against H9N2 and H5N1 Influenza Viruses in Mice

Overview

Journal Front Microbiol

Specialty Microbiology

Date 2022 Dec 2

PMID 36458187

Authors

Weigang Ren

Shuli Pei

Wenming Jiang

Meixia Zhao

Le Jiang

Honggang Liu

Yongxiang Yi

Mizhou Hui

Junwei Li

Affiliations

Soon will be listed here.

Abstract

H5N1 and H9N2 influenza viruses have been reported to cause human infections and are believed to have pandemic potential. The vaccine is an effective tool to prevent influenza virus infection. However, inactivated influenza vaccines sometimes result in low antigenicity as result leads to generating of incomplete immune protection in the form of low cellular and humoral immunity. While the low temperature adapted, traditional live attenuated influenza vaccine (LAIV) is associated with the potential risk to revert to a virulent phenotype, there appears an essential need for an alternative potent methodology to design and develop influenza vaccines with substantial safety and efficacy which may confer solid protection against H9N2 or H5N1 influenza virus infections. In the present study, a replication-deficient recombinant influenza virus, WM01ma-HA(H5), expressing hemagglutinin (HA) of both H9N2 and H5N1 subtypes was developed. The chimeric gene segment expressing HA(H5), was designed using the sequence of an open reading frame (ORF) of HA adopted from A/wild duck/Hunan/021/2005(H5N1)(HN021ma) which was flanked by the NA packaging signals of mouse-adapted strain A/Mink/Shandong/WM01/2014(H9N2)(WM01ma). Due to the absence of ORF of structural protein NA, the replication of this engineered H9N2 influenza viruses WM01ma-HA(H5) was hampered and but was well competent in MDCK cells stably expressing the NA protein of WM01ma. Intranasal vaccination of mice with WM01ma-HA(H5) stimulated robust immune response without any clinical signs and conferred complete protection from infection by H5N1 or H9N2 subtype influenza viruses.

Citing Articles

Pandemic preparedness through vaccine development for avian influenza viruses.

Cargnin Faccin F, Perez D Hum Vaccin Immunother. 2024; 20(1):2347019.

PMID: 38807261 PMC: 11141480. DOI: 10.1080/21645515.2024.2347019.

The Chinese Hamster Ovary Cell-Based H9 HA Subunit Avian Influenza Vaccine Provides Complete Protection against the H9N2 Virus Challenge in Chickens.

Zhu S, Nie Z, Che Y, Shu J, Wu S, He Y Viruses. 2024; 16(1).

PMID: 38275973 PMC: 10821000. DOI: 10.3390/v16010163.

References

Gomaa M, Khalil A, Kandeil A, Sabir J, Kayed A, Moatasim Y . Development of an effective contemporary trivalent avian influenza vaccine against circulating H5N1, H5N8, and H9N2 in Egypt. Poult Sci. 2019; 98(12):6289-6295. PMC: 6869764. DOI: 10.3382/ps/pez385. View

Proenca-Modena J, Macedo I, Arruda E . H5N1 avian influenza virus: an overview. Braz J Infect Dis. 2007; 11(1):125-33. DOI: 10.1590/s1413-86702007000100027. View

Saito T, Tanikawa T, Uchida Y, Takemae N, Kanehira K, Tsunekuni R . Intracontinental and intercontinental dissemination of Asian H5 highly pathogenic avian influenza virus (clade 2.3.4.4) in the winter of 2014-2015. Rev Med Virol. 2015; 25(6):388-405. DOI: 10.1002/rmv.1857. View

Hammitt L, Bartlett J, Li S, Rahkola J, Lang N, Janoff E . Kinetics of viral shedding and immune responses in adults following administration of cold-adapted influenza vaccine. Vaccine. 2009; 27(52):7359-66. DOI: 10.1016/j.vaccine.2009.09.041. View

Xu T, Wang C, Zhang R, Xu M, Liu B, Wei D . Carnosine markedly ameliorates H9N2 swine influenza virus-induced acute lung injury. J Gen Virol. 2015; 96(10):2939-2950. PMC: 4635477. DOI: 10.1099/jgv.0.000238. View

Lin Y, Shaw M, Gregory V, Cameron K, Lim W, Klimov A . Avian-to-human transmission of H9N2 subtype influenza A viruses: relationship between H9N2 and H5N1 human isolates. Proc Natl Acad Sci U S A. 2000; 97(17):9654-8. PMC: 16920. DOI: 10.1073/pnas.160270697. View

Chen J, Fang F, Yang Z, Liu X, Zhang H, Zhang Z . Characterization of highly pathogenic H5N1 avian influenza viruses isolated from poultry markets in central China. Virus Res. 2009; 146(1-2):19-28. DOI: 10.1016/j.virusres.2009.08.010. View

Kreijtz J, Bodewes R, van Amerongen G, Kuiken T, Fouchier R, Osterhaus A . Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice. Vaccine. 2006; 25(4):612-20. DOI: 10.1016/j.vaccine.2006.08.036. View

Swayne D . Impact of vaccines and vaccination on global control of avian influenza. Avian Dis. 2013; 56(4 Suppl):818-28. DOI: 10.1637/10183-041012-Review.1. View

10.

Li X, Tian B, Jianfang Z, Yongkun C, Xiaodan L, Wenfei Z . A comprehensive retrospective study of the seroprevalence of H9N2 avian influenza viruses in occupationally exposed populations in China. PLoS One. 2017; 12(6):e0178328. PMC: 5456037. DOI: 10.1371/journal.pone.0178328. View

11.

Masic A, Pyo H, Babiuk S, Zhou Y . An eight-segment swine influenza virus harboring H1 and H3 hemagglutinins is attenuated and protective against H1N1 and H3N2 subtypes in pigs. J Virol. 2013; 87(18):10114-25. PMC: 3753983. DOI: 10.1128/JVI.01348-13. View

12.

Hutchinson E, von Kirchbach J, Gog J, Digard P . Genome packaging in influenza A virus. J Gen Virol. 2009; 91(Pt 2):313-28. DOI: 10.1099/vir.0.017608-0. View

13.

Hoffmann E, Neumann G, Kawaoka Y, HOBOM G, Webster R . A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci U S A. 2000; 97(11):6108-13. PMC: 18566. DOI: 10.1073/pnas.100133697. View

14.

Peiris M, Yuen K, Leung C, Chan K, Ip P, Lai R . Human infection with influenza H9N2. Lancet. 1999; 354(9182):916-7. DOI: 10.1016/s0140-6736(99)03311-5. View

15.

Skeik N, Jabr F . Influenza viruses and the evolution of avian influenza virus H5N1. Int J Infect Dis. 2007; 12(3):233-8. PMC: 7110774. DOI: 10.1016/j.ijid.2007.07.002. View

16.

Olsen B, Munster V, Wallensten A, Waldenstrom J, Osterhaus A, Fouchier R . Global patterns of influenza a virus in wild birds. Science. 2006; 312(5772):384-8. DOI: 10.1126/science.1122438. View

17.

Sun Y, Liu J . H9N2 influenza virus in China: a cause of concern. Protein Cell. 2014; 6(1):18-25. PMC: 4286136. DOI: 10.1007/s13238-014-0111-7. View

18.

Landreth S, Detmer S, Gerdts V, Zhou Y . A bivalent live attenuated influenza virus vaccine protects against H1N2 and H3N2 viral infection in swine. Vet Microbiol. 2021; 253:108968. DOI: 10.1016/j.vetmic.2020.108968. View

19.

Ren W, Zhang C, Li G, Liu G, Shan H, Li J . Two genetically similar H9N2 influenza viruses isolated from different species show similar virulence in minks but different virulence in mice. Acta Virol. 2020; 64(1):67-77. DOI: 10.4149/av_2020_109. View

20.

Kim S, Kim Y, Park S, Kim E, Kwon H, Si Y . Vaccine Efficacy of Inactivated, Chimeric Hemagglutinin H9/H5N2 Avian Influenza Virus and Its Suitability for the Marker Vaccine Strategy. J Virol. 2017; 91(6). PMC: 5331804. DOI: 10.1128/JVI.01693-16. View